[Relationship between Shenzhen HBV genotype and precore/core promoter mutation and antiviral effects]
- PMID: 16642214
[Relationship between Shenzhen HBV genotype and precore/core promoter mutation and antiviral effects]
Abstract
Background: To study the relationship between hepatitis B virus genotyping Shenzhen isolates and HBV precore/core promoter mutation and antiviral effects.
Methods: The HBV genotyping of 165 patients with HBV was carried out with mAbs ELISA. HBV precore/core promoter mutation was detected with gene chip technology in 24 patients with CHB. The relationship between HBV genotyping and interferon, lamivudine effects was analyzed.
Results: (1) Out of 165 cases, 106 (64.2%) of type B but 48 (29.1%) of type C were found. Type B accounted for 95.4% in group ASC, and type C for 64.7%in group LC (P<0.05). (2) Precore/core promoter mutation was found in 16 cases (10 of type B, and 6 of type C) out of 24 cases. Out of 16 cases, precore/core promoter mutation (nt1896, 1862) was found in 10 cases (9 cases of type B and 1 case of type C), while basal core promoter mutation (BCP mutation, nt1762,1764) was found in 6 cases (1 case of type B and 5 of type C). (3) Among 27 patients with CHB HBAg (+) treated with interferon, 11 cases of type B but 1 case of type C were tested to be fully responsive to interferon. Among 29 patients with CHB HBAg (+) treated with lamivudine, 15 cases of type B but 3 cases of type C were tested to be continuously responsive to lamivudine.
Conclusion: (1) HBV genotype popularity in Shenzhen area was classified as type B the first and type C the second. (2) Type C seems more apt to develop BCP mutation and cirrhosis, and to be less responsive to interferon or lamivudine.
Similar articles
-
Comparative study of genotype B and C hepatitis B virus-induced chronic hepatitis in relation to the basic core promoter and precore mutations.J Gastroenterol Hepatol. 2005 Mar;20(3):441-9. doi: 10.1111/j.1440-1746.2004.03572.x. J Gastroenterol Hepatol. 2005. PMID: 15740490
-
Genetic heterogeneity of the precore and the core promoter region of genotype C hepatitis B virus during lamivudine therapy.J Med Virol. 2004 Jan;72(1):26-34. doi: 10.1002/jmv.10558. J Med Virol. 2004. PMID: 14635007
-
Differences of YMDD mutational patterns, precore/core promoter mutations, serum HBV DNA levels in lamivudine-resistant hepatitis B genotypes B and C.J Viral Hepat. 2007 Nov;14(11):767-74. doi: 10.1111/j.1365-2893.2007.00869.x. J Viral Hepat. 2007. PMID: 17927612
-
Is lamivudine effective on precore/core promoter mutants of hepatitis B virus?Hepatology. 2000 Nov;32(5):1172-4. doi: 10.1053/jhep.2000.20150. Hepatology. 2000. PMID: 11050072 Review. No abstract available.
-
Molecular methods in the diagnosis and management of chronic hepatitis B.Expert Rev Mol Diagn. 2010 Oct;10(7):921-35. doi: 10.1586/erm.10.75. Expert Rev Mol Diagn. 2010. PMID: 20964611 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical
Miscellaneous